Coagulopathy and the role of recombinant human activated protein C in sepsis and following polytrauma

By Dahabreh Ziad   Dimitriou Rozalia   Chalidis Byron   Giannoudis Peter V  

Expert Opinion on Drug Safety, Vol. 5, Iss. 1, 2006-01 ,pp. : 67-82

Informa Healthcare

Access to resources Recommend Favorite

An Algorithmic Computerised Order Entry Approach to Assist in the Prescribing of New Therapeutic Agents: Case Study of Activated Protein C at an Academic Medical Centre

By Michael A. Fischer   Craig M. Lilly   William W. Churchill   Lindsey R. Baden   Jerry Avorn  

Drug Safety, Vol. 27, Iss. 15, 2004-01 ,pp. : 1253-1261

Adis International

Access to resources Recommend Favorite

The epidemiology of severe sepsis syndrome and its treatment with recombinant human activated protein C

By Doig Christopher James   Laupland Kevin B   Zygun David A   Manns Braden J  

Expert Opinion on Pharmacotherapy, Vol. 4, Iss. 10, 2003-10 ,pp. : 1789-1799

Informa Healthcare

Access to resources Recommend Favorite

New therapeutic option for thromboembolism – dabigatran etexilate

By Nishio Hitoshi   Ieko Masahiro   Nakabayashi Toru  

Expert Opinion on Pharmacotherapy, Vol. 9, Iss. 14, 2008-10 ,pp. : 2509-2517

Informa Healthcare

Access to resources Recommend Favorite

mTOR inhibitors as a new therapeutic option for epilepsy

By Curatolo Paolo   Moavero Romina  

Expert Review of Neurotherapeutics, Vol. 13, Iss. 6, 2013-06 ,pp. : 627-638

Informa Healthcare

Access to resources Recommend Favorite